Brocriptin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brocriptin

Quick Facts

Property Description
Active ingredient Bromocriptine mesylate
Form Tablet or Capsule (Oral)
Pharmacological class Dopamine Agonist / Prolactin Inhibitor
General Purpose Restores chemical/hormonal balance
Origin Semi-synthetic Ergot Derivative

What Type of Medicine is Brocriptin and What is it Made Of?

Brocriptin is a prescription medication centrally defined by its active ingredient, Bromocriptine mesylate, which is formally classified as both an Ergot Alkaloid Derivative and a Dopamine Agonist. The compound itself is a semi-synthetic derivative, meaning its structure is chemically prepared from a naturally occurring base. The preparation is delivered in a solid oral form, typically as a tablet or capsule. As a single-ingredient product, Brocriptin is entirely focused on delivering the Bromocriptine mesylate consistently into the systemic circulation. This formulation is designed to allow for oral administration in the management of chronic neuroendocrine conditions.

How Does Brocriptin Generally Benefit the Body?

The core mechanism of Brocriptin provides a distinct general benefit by targeting specific neurotransmitter and endocrine pathways. It functions primarily by acting as an agonist on the Dopamine D2 receptors, effectively mimicking the body’s natural dopamine and thereby influencing nerve signaling. This action allows the drug to function as a Prolactin Inhibitor in suppressing the hormone's excessive release. This targeted intervention is generally used to restore chemical and hormonal balance within the body, offering foundational support for functions that are impaired by either excessive prolactin levels or relative dopamine deficiency in the relevant neural pathways.

Regulatory References

  1. Bromocriptine: MedlinePlus Drug Information

What side effects are possible with Brocriptin?

Possible Side Effects and Safety Information

The safety profile for Brocriptin is defined by official government regulatory documents which classify adverse reactions by frequency and potential severity across organ systems.

Frequency-Classified Adverse Reactions

Adverse effects commonly reported in clinical trials include nausea and headache (classified as very common), along with dizziness, vomiting, fatigue, and orthostatic hypotension (classified as common). Less common effects documented are psychiatric issues such as hallucinations and confusional states, and gastrointestinal issues like constipation.


Serious Adverse Reactions and Safety Restrictions

Official regulatory information emphasizes the potential for rare but serious adverse events involving major organ systems, including stroke, myocardial infarction (heart attack), and seizures.

  • Population Restriction (Postpartum Use): Regulatory authorities have significantly restricted the use of Brocriptin for the prevention or suppression of milk production after childbirth. This restriction is due to the documented risk of rare, serious, and potentially fatal adverse events, including stroke and heart attack, in this specific population.

  • Dose/Exposure-Related Pattern: Serious fibrotic reactions—involving the heart valves, pleura, and lungs—have been officially associated with high doses and prolonged treatment for other indications.

  • Contraindications: The medicine is contraindicated (should not be used) in individuals with uncontrolled high blood pressure, a history of serious cardiovascular disease, or known hypersensitivity to ergot alkaloids. Caution is required when used concomitantly with certain medications, such as strong CYP3A4 inhibitors, to manage the risk of increased drug concentration and severe hypotension.

Overdose and Emergency Response

The official regulatory documentation on Brocriptin (Bromocriptine mesylate) overdose describes specific manifestations and mandates immediate emergency action. Overdosage may be clinically identified by disturbances across the central nervous, cardiovascular, and gastrointestinal systems.

Documented Manifestations Primary Physiological Risk Mandated Management Focus
Confusion, Hallucinations, Drowsiness Severe Hypotension (low blood pressure) Supportive and Symptomatic Treatment
Nausea, Vomiting, Tachycardia Fast heart rate Fluid and Electrolyte Monitoring

A serious manifestation documented in official labeling is severe hypotension, which can be accompanied by dizziness, fainting, pallor, and fast heart rate. Other documented signs of acute overdosage include confusion, hallucinations, and excessive sweating.

Immediate medical help is required upon the suspicion of an overdose; official guidance states to seek medical attention straight away. Management is strictly supportive, as no specific antidote is known. Documented procedures for overdosage include gastrointestinal decontamination, such as gastric lavage or activated charcoal.

Furthermore, the treatment of severe hypotension requires specific interventions like patient positioning, administration of intravenous fluids, and the consideration of vasopressor medications if the condition persists. Careful supervision and recording of fluid intake and output is an essential regulatory requirement during the management of an acute overdosage.

Therapeutic Uses of Brocriptin

What Brocriptin Treats: Main Uses and Benefits

Brocriptin (Bromocriptine mesylate) is used to manage symptoms related to systemic imbalance and motor function impairment across several clinical domains. The medication is relevant for conditions presenting with systemic or localized discomfort, including Hyperprolactinemia (high prolactin levels), Prolactinoma (pituitary tumors), Parkinson’s disease, Acromegaly, and Type 2 Diabetes Mellitus.


Restoration of Hormonal Balance and Reproductive Function

This domain is relevant in contexts marked by increased discomfort or tension stemming from pituitary overproduction. Brocriptin is used for managing symptom clusters such as the absence of menstrual periods (amenorrhea), abnormal milk production (galactorrhea), and associated infertility. This provides supportive relief when symptoms interfere with routine activities and may assist in managing the volume of the prolactin-secreting tumor.

Supportive Management of Motor and Metabolic Symptoms

Brocriptin plays a role in addressing symptoms related to increased neurological activity associated with Parkinson’s disease, helping to ease motor difficulties like rigidity (stiffness) and tremor. It also is applied in addressing metabolic concerns in Type 2 Diabetes Mellitus as an adjunctive therapy and is relevant for easing symptoms related to systemic imbalance in Acromegaly. This contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.


Quick Facts

Domain Primary Symptom/Condition Therapeutic Benefit
Neuroendocrine Hyperprolactinemia / Prolactinoma Supports maintenance of functional stability
Neurological Parkinson's Motor Impairment Contributes to easing overall symptom load
Metabolic Type 2 Diabetes Mellitus Assists with metabolic management

Regulatory References

  1. Bromocriptine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Brocriptin?

Brocriptin is primarily approved for use in adults for all labeled conditions, including the geriatric population. However, official regulatory documents strictly define several populations and conditions that restrict or prohibit its use.

Absolute Prohibitions

The medicine is contraindicated (must not be used) in patients with known hypersensitivity to bromocriptine or other ergot alkaloids. Prohibition also applies to patients with uncontrolled systemic hypertension or pregnancy-induced hypertension. Furthermore, Brocriptin is contraindicated for women who are nursing or breastfeeding and those in the postpartum period for specific uses.

Conditional Use and Restrictions

Use is not recommended or requires caution in patients with a history of severe psychiatric disorders or fibrotic conditions like pleural or pericardial fibrosis. Caution is also warranted for patients with hepatic impairment due to the medicine's extensive metabolism. Pediatric use is largely not established for most indications, and during pregnancy, treatment should generally be discontinued unless medically essential.

What should I know about interactions with other medicines?

Brocriptin Interactions with Other Medicines and Products

The interaction profile of Brocriptin (Bromocriptine mesylate) is defined by its metabolism and its classification as an ergot alkaloid derivative.

Interaction Scope

Property Description
Medicinal product categories with documented interactions: Dopamine receptor antagonists (e.g., neuroleptics, metoclopramide), Ergot-related drugs (e.g., ergotamine, triptans), Strong CYP3A4 inhibitors (e.g., azole antimycotics, HIV protease inhibitors), Moderate CYP3A4 inhibitors, Highly protein-bound therapies, Antihypertensive medications.
Mechanistic basis of interactions (only if stated in label): Pharmacokinetic: Brocriptin is extensively metabolized by CYP3A4, meaning inhibitors increase its plasma levels (exposure) and inducers may decrease them. Pharmacodynamic: Additive effects occur with agents like dopamine antagonists, which may diminish effectiveness, and with other ergot agents, which can increase vasoconstrictive risk.
Timing-based interaction rules (if applicable): Co-administration with ergot-related drugs is officially not recommended within 6 hours of Brocriptin dosing.
Population-specific interaction notes (if applicable): Hepatic Impairment may increase plasma levels; Postpartum Patients are subject to formal contraindication due to reported adverse reactions.

Official Interaction Statements:

  • Co-administration with strong CYP3A4 inhibitors is officially avoided due to the risk of significantly increased Brocriptin exposure.
  • Concomitant use with ergot-related drugs and certain migraine therapies like triptans is contraindicated due to risk of additive side effects.
  • The official label mandates a dose restriction (not to exceed 1.6 mg daily) during concomitant use of a moderate CYP3A4 inhibitor (e.g., erythromycin).
  • Brocriptin is highly protein-bound and may increase the unbound fraction of other highly protein-bound therapies (e.g., salicylates, sulfonamides).
  • Co-ingestion with alcohol may potentiate nervous system side effects, and grapefruit juice can increase circulating levels.

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure primarily through its CYP3A4 metabolism and its activity as an ergot derivative. This mandates a spectrum of constraints, including formal contraindications against strong CYP3A4 inhibitors, specific dose restrictions for moderate inhibitors, timing rules for ergot agents, and caution when co-administering with other highly protein-bound or blood pressure-lowering medications.

Mechanism of Action

How Brocriptin Works

Brocriptin ( Bromocriptine mesylate) exerts its action through the direct agonism of Dopamine D2 Receptors ( D2 R), which allows it to engage and modulate three primary biological systems: neuroendocrine, motor, and metabolic.


Pituitary Hormone Regulation

The drug acts on D2 receptors located on the lactotroph cells of the anterior pituitary gland, which are responsible for producing the hormone Prolactin ( PRL). Activating these receptors initiates an inhibitory cellular cascade that directly suppresses the synthesis and secretion of Prolactin, leading to a physiological reduction in the hormone's circulating levels.


Central Motor and Dopaminergic Signaling

Brocriptin stimulates D2 receptors within the Nigrostriatal pathway of the central nervous system ( CNS). By mimicking dopamine in these motor control centers, the mechanism helps to restore the appropriate dopamine tone essential for neural output to muscle groups, which contributes to the modulation of motor function.


Modulation of Metabolic Tone

The D2 receptor agonism within the hypothalamic nuclei responsible for regulating autonomic nervous system outflow alters the sympathetic tone. This central adjustment is believed to contribute to peripheral glucose disposal and the modulation of glucose homeostasis.

Dosage and Administration Information

Brocriptin (Bromocriptine mesylate) is administered through the oral route as a tablet or capsule, and its use follows a systematic, condition-specific titration protocol. The entire dose is taken with food to support proper tolerability.

Administration and Dosing

Condition Type Initial Daily Dose Maintenance Dose Range Max Daily Dose
Hyperprolactinemia 1.25 mg to 2.5 mg 2.5 mg to 15 mg 30 mg
Parkinson's Disease 2.5 mg (as 1.25 mg twice daily) 10 mg to 30 mg 100 mg
Type 2 Diabetes 0.8 mg (quick-release form only) 1.6 mg to 4.8 mg 4.8 mg

Treatment is initiated at a low dose, such as 1.25 mg or 2.5 mg once daily, and then gradually increased in small increments (titrated) over several days or weeks until the optimal therapeutic dosage is established. This frequency of dose escalation varies by indication and is a standard part of the use pattern.

Special Timing and Population Rules

For the quick-release formulation used in Type 2 Diabetes, the total daily dose is taken within two hours after waking in the morning along with food. If this specific morning dose is missed, the dose should not be doubled on the following morning. For older adults, dose selection is typically cautious, often starting at the lower end of the dose range. In cases of known hepatic impairment, caution is used as dosage adjustment may be necessary due to the extensive liver metabolism of the drug.

Recent Clinical Evidence

Research evidence / Overview of studies for Brocriptin


Evidence for Hormonal Conditions: Hyperprolactinemia and Prolactinoma

Research has extensively studied Brocriptin in the context of conditions related to the overproduction of the hormone prolactin, such as Hyperprolactinemia and the presence of a Prolactinoma (a pituitary tumor). Researchers primarily examined the agent's potential role by monitoring serum prolactin concentrations, assessing changes in the volume of the tumors, and evaluating the restoration of reproductive function. Studies reported measurements showing patterns in both prolactin levels and tumor volume. The evidence base contributes to the broader evidence landscape. Comparative evidence is lacking for all key outcomes against other agents that were studied for the same purpose, meaning the evidence quality varies across studies.


Evidence for Metabolic Control: Type 2 Diabetes Mellitus

Research into the agent for Type 2 Diabetes Mellitus is grounded in large-scale, placebo-controlled trials and systematic reviews, focusing on a specific quick-release formulation. Researchers examined key metabolic outcomes by measuring glycated hemoglobin ( HbA1c) and Fasting Plasma Glucose levels. A large-scale safety study was conducted which monitored the agent's association with a composite measure of cardiovascular outcomes (such as heart attack or stroke) over a 52-week period. Scientific research is ongoing regarding the patterns indicated on cardiovascular outcomes in diabetes patients.


Evidence for Movement Disorders: Parkinson’s disease

Research examined Brocriptin in clinical trials, including randomized studies and systematic reviews, in the context of Parkinson's disease. The research explored short-term symptom changes in populations including both newly started patients and those with conditions involving periods of heightened symptoms. The studies monitored outcomes related to motor impairment and disability using functional rating scales. Comparative studies data show patterns related to motor complications when the agent was observed in trials with standard therapies. The overall evidence supporting certain outcomes certainty remains low to very low.


What is Still Uncertain About the Research

The available evidence contributes to the broader evidence landscape, but several uncertainties remain. Long-term effects are not fully established on overall symptom patterns and outcomes over a decade or more across the full range of conditions for which the agent was studied for. For certain indications, sample sizes were modest in some pivotal trials, meaning results apply only to the populations studied. Research is ongoing to address some of these limitations and clarify specific mechanisms.

Frequently Asked Questions (FAQ)

Common questions about Brocriptin (FAQ)

Q: Can Brocriptin affect my libido or sexual function?

A: Regulatory documents and postmarketing reports have included descriptions of impulse control disorders in some patients taking dopamine receptor agonists. Official information describes reports of intense, uncontrolled urges, such as hypersexuality (increased sexual urges), in association with this class of medication.

Q: Are there any dietary restrictions or foods to avoid while taking Brocriptin?

A: Official product information advises taking the medication with food. Co-ingestion with grapefruit juice can increase the amount of drug circulating in the body, and alcohol use may increase nervous system side effects.

Q: Are there specific warnings for people with a history of peptic ulcers when taking Brocriptin?

A: Monitoring for signs and symptoms that could be related to a peptic ulcer is advised for patients receiving long-term treatment for certain conditions. Official prescribing information advises caution or monitoring for individuals with certain histories.

Q: Is Brocriptin safe to take with birth control pills?

A: For females using a specific brand of this medication who are not seeking pregnancy, official product information suggests the use of an effective non-hormonal method of contraception instead of oral contraceptives (birth control pills).

Q: Are there different brands or forms of Brocriptin available?

A: The active ingredient (bromocriptine) is available under different brand names, such as Parlodel and Cycloset. The product is also supplied in different solid oral forms, including an oral tablet, a capsule, and a specific quick-release tablet formulation.

Q: Is there a generic version of Brocriptin available?

A: A generic version of bromocriptine mesylate is generally available. However, a therapeutically equivalent generic for the specific quick-release formulation used to treat Type 2 Diabetes is not currently available in the United States.

Q: Does Brocriptin affect fertility in general?

A: The medication is approved for use in men and women with infertility when it is associated with abnormally high prolactin levels (hyperprolactinemia). By reducing these levels, the medication may help restore normal reproductive functions, such as ovulation or menstruation.

Q: Can Brocriptin affect my sleep?

A: Official documents list both somnolence (drowsiness) and, less commonly, insomnia (sleeplessness) as possible adverse effects. Reports of sudden sleep onset have also been documented in official product information, particularly in patients being treated for Parkinson's disease.

Q: How should Brocriptin be stored?

A: Storage requires keeping the container tightly closed, protected from light and moisture, and maintaining Controlled Room Temperature. Unused or expired medication must not be disposed of in household waste or flushed down the toilet. Proper disposal according to local regulations can be determined by consulting a healthcare professional or pharmacist.

Q: What is the main difference between Brocriptin and other common treatments for the same condition?

A: Brocriptin is formally classified as a semi-synthetic ergot derivative that acts as a dopamine receptor agonist. It is described as a nonhormonal agent that works by stimulating dopamine receptors, which helps inhibit the excessive secretion of the hormone prolactin.

Q: How long does it typically take to notice the effects of Brocriptin?

A: The onset of action, meaning when the drug begins to take effect after an oral dose, is typically described as being around two hours. However, the full therapeutic response is often achieved only after a period of gradual dose increases (titration) over several weeks.

Q: Is it normal to feel a little dizzy or light-headed when first starting Brocriptin?

A: Official information indicates that dizziness, light-headedness, and orthostatic hypotension (a drop in blood pressure when standing) are listed as common side effects. These effects are noted to occur more frequently when treatment is first started or immediately following a dose increase.

Q: What are the most common side effects of Brocriptin that people mention online?

A: The most frequently reported adverse reactions identified across clinical studies include nausea, headache, dizziness, vomiting, fatigue, and orthostatic hypotension. These are classified as very common or common in official regulatory documents.

Q: Can older adults typically use Brocriptin without special precautions?

A: Official regulatory documents indicate that dose selection for older adults requires caution. Treatment should generally be initiated at the lower end of the established dose range for their condition.

Q: Has the FDA issued any recent safety warnings about Brocriptin?

A: The FDA periodically issues enforcement reports that have included recalls for some lots of generic bromocriptine mesylate capsules. These recalls were generally related to product quality issues, such as failing impurities or degradation tests.

Q: What is the evidence base for using Brocriptin for type 2 diabetes?

A: The evidence base for the quick-release formulation includes large-scale, randomized controlled trials. These studies examined key metabolic outcomes like lowering glycated hemoglobin ( HbA1c) levels, and a comprehensive safety study that monitored cardiovascular outcomes.

Q: Are there any common skin reactions or rashes associated with Brocriptin?

A: A very serious allergic reaction to the drug is rare, but official warnings indicate that symptoms such as rash and itching are considered signs of a potentially serious allergic reaction.

Q: Are there pediatric uses for Brocriptin?

A: Pediatric use is generally not established for most conditions. However, the medicine is specifically indicated for children between 11 and 15 years of age to treat hyperprolactinemia-associated dysfunctions.

Q: Is there a link between Brocriptin and increased impulsive behavior?

A: Official warnings mention the potential for patients to experience intense, uncontrolled urges while taking this type of medication. These can include increased gambling urges, increased sexual urges, uncontrolled spending, or other intense urges.

Q: Does Brocriptin work immediately after the first dose?

A: The onset of the drug's effect is typically noted about two hours after the first dose. However, achieving the full therapeutic benefit often requires gradually increasing the dose over time, which is known as titration.

Q: Is it okay to drive or operate heavy machinery while taking Brocriptin?

A: Official warnings state that due to the risk of somnolence (drowsiness) and sudden sleep onset, operating heavy machinery or driving is not recommended until the effects on alertness are known.

How should Brocriptin be stored and disposed of?

How to Store and Dispose of Brocriptin

Brocriptin (bromocriptine mesylate) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from temperature extremes. It is required to protect the medication from freezing and excess heat.

Handling and Protection

The container must be kept tightly closed and stored away from light and moisture. For child safety, the product must be stored out of the reach and sight of children.

Disposal

Do not use the medicine after the expiration date on the package. Unused or expired Brocriptin must not be disposed of in household waste or flushed down the toilet. Consult a healthcare professional or pharmacist on the proper method of disposal according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brocriptin found in:

A-Z Index: